Saghmos Therapeutics Secures U.S. Patent for Phase 3-Ready Cardiorenal Modulator ST-62516

Saghmos Therapeutics, Inc., a biopharmaceutical company based in Greenwich, Connecticut, has recently achieved a significant milestone. The U.S. Patent and Trademark Office (USPTO) has granted the company U.S. Patent No. 11,986,473, titled "Prevention and/or Treatment of Contrast-Induced Acute Kidney Injury." This patent, which extends exclusivity until 2037, covers the company's Phase 3-ready drug ST-62516 (trimetazidine), designed as a cardiorenal metabolic modulator. The patent's broad claims include reducing the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) in patients undergoing procedures that involve contrast dyes.

ST-62516 is being developed specifically to mitigate the risks associated with contrast procedures, such as percutaneous coronary intervention (PCI), which are frequently performed to treat heart conditions. The relationship between cardiovascular disease, kidney disease, and metabolic disorders has been collectively termed CKM Syndrome. Patients suffering from CKM Syndrome face heightened risks of adverse outcomes after undergoing contrast procedures. ST-62516 aims to address this critical unmet medical need by providing a solution that could benefit not only patients with CKM Syndrome but also a broader patient population undergoing PCI.

The founder and CEO of Saghmos Therapeutics, Dr. Anna Kazanchyan, expressed enthusiasm about the expansion of the company's intellectual property portfolio, which now includes two issued U.S. patents and an additional patent in Japan. This growth reflects the company's ongoing efforts to innovate and protect its therapeutic solutions.

According to data from the American Heart Association, approximately one-third of U.S. adults possess three or more risk factors for CKM Syndrome. Each year, over one million PCI procedures are performed in the United States, with about half of the patients either having CKM Syndrome or being aged 75 and older. These factors, combined with procedure-related risks, significantly affect the safety and outcomes of PCI, increasing the likelihood of AKI and MACKE. This represents a substantial medical need, as there are currently no FDA-approved drugs specifically for this condition. ST-62516 has the potential to fill this gap and improve the safety of PCI for a wide range of patients.

Saghmos Therapeutics is preparing to advance ST-62516 into a Phase 3 clinical trial. The company has recently collaborated with the Duke Clinical Research Institute (DCRI) to refine and plan the execution of this pivotal study. This partnership is expected to optimize the trial's design and operational aspects, bolstering the potential success of ST-62516 in addressing this significant healthcare challenge.

In summary, the recent patent grant for ST-62516 marks a pivotal step for Saghmos Therapeutics in its mission to tackle the risks associated with contrast-induced procedures. With the Phase 3 study on the horizon and a solid intellectual property foundation, the company is well-positioned to make a meaningful impact on the treatment of CKM Syndrome and beyond, ultimately benefiting a wide array of patients undergoing PCI.